Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Curve vs HealthRX

By GLP-1 ScorecardUpdated

CurveFactor scores not reassessed.
Site position #303

Lower score

HealthRXFactor scores not reassessed.
Site position #34

Higher score

Score comparison

HealthRX has the higher recorded score — 77.5/100 to 61.9/100.

HealthRX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. HealthRX advertises a $39 first month on three-, six- and twelve-month injection plans, with a higher month-to-month option; a plan's remaining monthly payments stay due if you cancel early.

Before you choose

Curve does not publish a semaglutide price, so its Curve review sets out what it does disclose, while the HealthRX review explains the conditions attached to HealthRX's figure. The semaglutide cost page compares published rates across the field. Ask Curve for a written total before treating either one as the cheaper choice.

If neither one fits, Curve vs Invigor Medical and Eve vs HealthRX compare each of them with another graded program, and the list of alternatives to Curve ranks the programs closest to Curve on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.

We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.

Factor by factor

These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.

Cost valueHealthRX +27
58
85
Dose & formulationEven
64
64
Clinical oversightHealthRX +19
68
87
Labs & monitoringHealthRX +30
52
82
FulfillmentCurve +11
97
86
Contract termsHealthRX +23
20
43
Curve · top barHealthRX · bottom bar

The numbers

Swipe or scroll to compare both providers.

MetricCurveHealthRX
WeighScore61.9/10077.5/100
GradeCC+
Site position#303#34
SemaglutideCurrent price not verified$39 first month, then $125/month on a 3-month plan ($115 on 6 months, $97 on 12); month to month $109 first month, then $139/month
TirzepatideCurrent price not verified$39 first month, then $219/month on a 3-month plan ($179 on 6 months, $159 on 12); month to month $109 first month, then $239/month
CoverageCurrent coverage not verifiedAll 50 states claimed; subject to clinical eligibility
Brand-name accessNot confirmedNot confirmed
Oral / sublingualNot confirmedNot confirmed
Curve

Site position #303 · C

Factor scores not reassessed.

Strengths

  • Archived homepage names its care network and pharmacy partner

What to consider

  • Current enrollment and checkout terms remain unverified
HealthRX

Site position #34 · C+

Factor scores not reassessed.

Strengths

  • First payment and recurring monthly charge shown together for every plan
  • Medication if prescribed, review, instructions and overnight shipping included; no separate GLP-1 membership fee stated
  • A month-to-month option carries no minimum term
  • Full refund promised if clinical approval is declined

What to consider

  • On 3-, 6- and 12-month plans the remaining monthly payments stay due after an early cancellation
  • Assigned medical practice and dispensing pharmacy not named on reviewed public pages
  • Refund promises for unshipped doses need reconciliation with restrictions after dispensing
  • Injection supplies, clinical response time and monitoring cadence unconfirmed

Featured provider

HealthRX

Factor scores not reassessed.

HealthRX scores 77.5/100 (C+). HealthRX advertises a $39 first month on three-, six- and twelve-month injection plans, with a higher month-to-month option; a plan's remaining monthly payments stay due if you cancel early.

Commercial relationships affect this placement. The score comparison above is separate.

Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.

← Back to the scorecard